GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan
GE HealthCare has completed its acquisition of Sumitomo Chemical’s 50% stake in Nihon Medi-Physics (NMP), giving it full ownership. As part of GE HealthCare, NMP, already a leading radiopharmaceutical company in Japan, is positioned to enhance patient access to next-generation radiopharmaceuticals that enable detection and diagnosis of disease Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics segment, will also become President of NMP.
GE HealthCare Technologies Inc. (GE HealthCare or the Company) (Nasdaq: GEHC) has completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP), from Sumitomo Chemical, giving it full ownership. As part of GE HealthCare, NMP can further build on its expertise in developing and manufacturing proprietary and in-licensed radiopharmaceuticals used in single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures to detect and diagnose disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250330506353/en/
Nihon Medi-Physics headquarters and radiopharmaceutical imaging agents about to go through labelling and packing process.
Kevin O’Neill, President & CEO of GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment, who will also become President of NMP, said: “We are delighted to welcome Nihon Medi-Physics to GE HealthCare, increasing our existing footprint and offering in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country. Japan is on a path to becoming a leader in the $7 billion molecular imaging global market1 and a center of excellence for Asian markets. As part of GE HealthCare, NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring next-generation radiopharmaceuticals to the Japan market and beyond.”
NMP’s product portfolio includes GE HealthCare radiopharmaceuticals used to enable molecular imaging across neurology, cardiology and oncology procedures. NMP, headquartered in Tokyo, was formed in 1973 and generated revenues of 28.2B JPY (~$183M) in 2023. GE HealthCare acquired Amersham plc in 2004, and subsequently held a 50% stake in NMP.
The Company expects this transaction to be neutral to Adjusted EPS2 in year one and accretive thereafter.
GE HealthCare was advised by Solomon Partners Securities, LLC.
The intent to acquire the remaining 50% stake in NMP was announced in December 2024.
Forward-Looking Statements
This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the expected results of the transaction, future market conditions, and the Company’s performance, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; and the Company may assume unexpected risks and liabilities. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.
About GE HealthCare Technologies Inc.
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, dedicated to providing integrated solutions, services, and data analytics to make hospitals more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected, and compassionate care, while simplifying the patient’s journey across the care pathway. Together our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics businesses help improve patient care from diagnosis, to therapy, to monitoring. We are a $19.6 billion business with approximately 51,000 colleagues working to create a world where healthcare has no limits.
GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.
Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.
1 GE HealthCare estimated global end markets as of December 2023, and estimated market CAGR 2024–2028.
2 Non-GAAP financial measure. See our earnings release dated February 13, 2025 for the definition of Adjusted EPS.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250330506353/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zema Global Strengthens Analytics Offering with Acquisition of cQuant.io1.4.2025 21:58:00 CEST | Press release
David Leevan, CEO of cQuant.io, appointed President of Zema Global, to help drive growth and innovation across combined business.cQuant.io will operate as a subsidiary under the brand “A Zema Global Company,” reflecting the strategic alignment and shared vision of both firms. Zema Global, a leading provider of data management and analytics solutions for companies engaged in the energy, commodities and financial sectors, today announced the acquisition of cQuant.io, an industry leader in analytic solutions for energy and commodity companies. The acquisition, supported by Zema Global’s existing investor FTV Capital, marks a significant step in the company’s mission to deliver real-time, enterprise-grade insights that transform how energy and commodity firms operate. Andrea Remyn Stone, CEO of Zema Global, said: “This is a pivotal moment for Zema Global and for our customers. By bringing cQuant.io into the fold, we are taking a major step toward delivering truly end-to-end data and analyt
Kinaxis Partners With Databricks to Accelerate AI-Powered Supply Chain Orchestration1.4.2025 17:01:00 CEST | Press release
Kinaxis Maestro™ and Databricks’ Data Intelligence Platform come together to power faster insights, unified data, and scalable AI across global supply chains Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, and Databricks, the data and AI company, today announced a partnership to set a new standard for intelligent supply chain decision-making. By combining Kinaxis Maestro™, the only AI-native platform purpose-built for end-to-end supply chain orchestration, with the scalability and governance of the Databricks Data Intelligence Platform, the companies are enabling organizations to unify their data, accelerate AI adoption, and respond to change with speed and confidence. This collaboration meets growing demand for more agile, data-driven supply chains. It strengthens Maestro’s supply chain data fabric, helping companies bring together information from core systems like inventory and procurement, alongside external inputs such as weather patterns and market s
Museum Centre Vapriikki: A Finnish study reveals: Longer breastfeeding in the Middle Ages – Weaning began at age one in the 1800s1.4.2025 17:00:00 CEST | Press release
A research project launched by the Museum Centre Vapriikki has shed new light on infant feeding practices in medieval and early modern Finland. Led by PhD Tiina Väre and PhD Ulla Nordfors—a bioarchaeologist at Vapriikki and the University of Turku—the study examined early childhood diets using isotopic analysis of teeth from 13th–19th century individuals buried at the ruined St. Michael’s Church in Pälkäne. The results were published in Journal of Archaeological Science: Reports. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250401865015/en/ According to a new study by Vapriikki, individuals who lived to adulthood in the Middle Ages received breast milk until they were over two years old. Photo: Ulla Nordfors All studied individuals had been breastfed in infancy, but the timing of weaning differed. Individuals who survived into adulthood during the medieval period had received breast milk beyond the age of two, whereas thos
Capcom Continues Marketing Partner Deal with the Japan Volleyball Association!1.4.2025 15:00:00 CEST | Press release
– Supporting the heated competition of Japan men’s and women’s national volleyball team as Top Partner – Capcom Co., Ltd. (TOKYO:9697) today announced that as of April 2025 it has extended its official sponsorship deal with the Japan Volleyball Association (President: Shunichi Kawai; Shibuya-ku, Tokyo; JVA, below), continuing Capcom’s role as a JVA Top Partner for both the Japan men’s and women’s national volleyball teams. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250401538680/en/ The JVA x Capcom Top Partner Logo With its corporate philosophy of being a Creator of Entertainment Culture that Stimulates Your Senses, Capcom aims to contribute to building a richer society by delivering smiles and excitement to more than 220 countries and regions around the world through its superior game content. Guided by this philosophy, Capcom shares the JVA’s goal of fostering humanity while contributing to the healthy development of c
RAW Nutrition Joins Forces with The Quality Group in Category-Defining Co-Ownership and Partnership1.4.2025 15:00:00 CEST | Press release
In the Category-Defining Announcement, RAW Nutrition Will Strengthen Its Position in the United States, While Staying True to Its Mission and Loyal Community RAW Nutrition, the fast growing sport nutrition brand that combines unmatched quality with cutting-edge formulation, today announced its partnership with The Quality Group, the European leader in performance nutrition known for its state-of-the-art product development and uncompromising quality standards. RAW Nutrition, which was recognized in 2024 as the fastest-growing consumer packaged goods company by Inc. 5000, built its reputation by delivering high-performance nutrition trusted by athletes at the highest level, and this strategic partnership allows the company to take that commitment to growth and innovation to the next level. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250401643282/en/ RAW Nutrition Joins Forces with The Quality Group in Category-Defining Co-
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom